<DOC>
	<DOCNO>NCT00388986</DOCNO>
	<brief_summary>This study assess potential pharmacodynamic potential pharmacokinetic interaction GK Activator ( 2 ) glyburide , type 2 diabetes patient adequately control glyburide standard prescribe therapy . Patients enter study take dose glyburide ( 10-20mg po daily ) prescribe prior study start . GK Activator ( 2 ) 100mg bid add 5 day . From day 6-12 patient receive GK Activator ( 2 ) monotherapy , day 13 GK Activator ( 2 ) discontinue glyburide treatment re-started . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study GK Activator ( 2 ) Glyburide Patients With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>adult patient , age 1875 year ; type 2 diabetes mellitus ; currently glyburide 1020 mg/day &gt; =3 month ; untreated , take antidiabetic statin therapy &gt; =2 week study start . type 1 diabetes mellitus , latent autoimmune diabetes adult ; diabetic neuropathy , retinopathy nephropathy ; patient treat insulin PPAR gamma agonist 6 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>